CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma

Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.